Inhibrx Biosciences, Inc. (INBX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences NASDAQ: INBX CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval date looming, this concentrated insider buying signals a high-probability valuation reset and sets the stage for a potential short squeeze.
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma was accepted by the FDA, with a PDUFA target action date of April 14, 2027. Company reported positive interim data for ozekibart in 3rd/4th-line CRC and strong phase 2 results for INBRX-106 plus KEYTRUDA in HNSCC.
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data shared yesterday, with pronounced efficacy in HPV+ patients, but market response remains muted.
Inhibrx Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 27 | $916.79 | $2,302.02 | $1,385.23 | 151.1% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 2,818 | $267,010 | $240,262.68 | -$26,747.32 | -10.02% |
| BG Bart Gancher Intech Investment Management LLC | 2,172 | $207,426 | $196,566 | -$10,860 | -5.24% |
| BP Benoit Piscione Credit Industriel Et Commercial | 64,217 | $916,377 | $5.48M | $4.56M | 497.48% |
| CD Charlie Durham Sterling Capital Management LLC | 61 | $2,054.48 | $5,200.86 | $3,146.38 | 153.15% |
Inhibrx Biosciences, Inc. (INBX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inhibrx Biosciences, Inc. ever had a stock split?
Inhibrx Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark Lappe CEO | NASDAQ (NGS) Exchange | 45720N103 CUSIP |
| US Country | 110 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Inhibrx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutic candidates. Since its inception in 2009, the company has been committed to addressing unmet medical needs across various diseases, primarily in oncology and genetic disorders. Leveraging advanced technology and scientific research, Inhibrx, Inc. aims to bring forth novel treatments that can significantly improve patient outcomes. Headquartered in La Jolla, California, the company is at the forefront of biotechnology research, holding promising potential in its developmental pipeline. Its strategic partnerships with industry leaders like 2seventy bio, Inc. and Bristol-Myers Squibb Company further underscore its commitment to advancing healthcare solutions.
Products and Services
INBRX-109
INBRX-109 is a tetravalent therapeutic candidate that targets death receptor 5 (DR5). This innovative approach is aimed at treating various types of cancers, including chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma. Currently, INBRX-109 is undergoing Phase 2 clinical trials, highlighting its potential in oncology.
INBRX-101
Another notable candidate in Inhibrx's pipeline is INBRX-101. This product is designed as an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic, targeting patients suffering from AAT deficiency. By addressing this genetic disorder at its source, INBRX-101 aims to offer a new treatment paradigm for those affected. The candidate is in Phase 1 clinical trials, reflecting its early-stage development.
INBRX-106
INBRX-106 stands out as a hexavalent agonist of OX40, geared towards treating a broad range of oncology indications. Through its innovative mechanism of action, INBRX-106 is designed to stimulate the immune system in a manner that specifically targets and attacks cancer cells. The development of INBRX-106 underlines Inhibrx’s commitment to expanding its oncology portfolio with cutting-edge therapeutic solutions.
Contact Information
